Cancer Treatment Reviews
Volume 26, Issue 6 , Pages 411-427 , December 2000

Allogeneic stem cell transplantation for the non-Hodgkin’s lymphomas and Hodgkin’s disease

References 

    REFERENCES
  1. Salzman DE, Briggs AD, Vaughan WP. Bone marrow transplantation for non-Hodgkin’s lymphoma: a review. Am J Med Sci. 1997;313:228–235
  2. Reece DE, Phillips GL. Intensive therapy and autotransplantation in Hodgkin’s disease. Stem Cells (Dayt). 1994;12:477–493
  3. Frei E, Canellos GP. Dose: a critical factor in cancer chemotherapy. Am J Med. 1980;69:585–594
  4. Horowitz MM, Gale RP, Sondel PM. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555–562
  5. Storb R. Preparative regimens for patients with leukemias and severe aplastic anemia (overview): biologic basis, experimental animal studies, and clinical trials at the Fred Hutchinson Cancer Research Center. Bone Marrow Transplant. 1994;14:S1–S3
  6. Passweg JR, Rowlings PA, Armitage JO. Report from the International Bone Marrow Transplant Registry and Autologous Blood and Marrow Transplant Registry—North America. Clin Transpl. 1995;117–127
  7. Goldman JM, Schmitz N, Niethammer D, Gratwohl A. Allogeneic and autologous transplantation for haematological diseases, solid tumours, and immune disorders: current practice in Europe in 1998. Bone Marrow Transplant. 1998;21:1–7
  8. Linch DC, Winfield D, Goldstone AH. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet. 1993;341:1051–1054
  9. Philip T, Guglielmi C, Hagenbeek A. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333:1540–1545
  10. Haioun C, Lepage E, Gisselbrecht C. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin’s lymphoma: updated results of the prospective study LNH87-2. Groupe d’Etude des Lymphomes de I’Adulte. J Clin Oncol. 1997;15:1131–1137
  11. Norton AJ. Classification of non-Hodgkin’s lymphomas. Baillieres Clin Haematol. 1996;9:641–652
  12. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin. 1998;48:6–29
  13. Pittaluga S, Bijnens L, Teodorovic I. Clinical analysis of 670 cases in two trials of the European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group subtyped according to the Revised European–American Classification of Lymphoid Neoplasms: a comparison with the Working Formulation. Blood. 1996;87:4358–4367
  14. De Wolf-Peeters C, Pittaluga S. Further considerations on the Revised European–American Lymphoma classification. Curr Opin Oncol. 1996;8:366–370
  15. Cancer. 1982;49:2112–2135
  16. Skarin AT, Dorfman DM. Non-Hodgkin’s lymphomas: current classification and management. CA Cancer J Clin. 1997;47:351–372
  17. Marafioti T, Hummel M, Anagnostopoulos I. Origin of nodular lymphocyte-predominant Hodgkin’s disease from a clonal expansion of highly mutated germinal-center B cells. N Engl J Med. 1997;337:453–458
  18. Longo DL, Banks PM, Hoppe RT. Hodgkin’s disease. Rev Invest Clin. 1994;73–83
  19. Longo DL, Duffey PL, Young RC. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin’s disease after combination chemotherapy: the low probability for cure. J Clin Oncol. 1992;10:210–218
  20. Bolwell B, Goormastic M, Andersen S. Durability of remission after ABMT for NHL: the importance of the 2-year evaluation point. Bone Marrow Transplant. 1997;19:443–448
  21. Weisdorf DJ, Andersen JW, Glick JH, Oken MM. Survival after relapse of low-grade non-Hodgkin’s lymphoma: implications for marrow transplantation. J Clin Oncol. 1992;10:942–947
  22. Dann EJ, Daugherty CK, Larson RA. Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin’s disease and non-Hodgkin’s lymphoma. Bone Marrow Transplant. 1997;20:369–374
  23. Mendoza E, Territo M, Schiller G, Lill M, Kumkel L, Wolin M. Allogeneic bone marrow transplantation for Hodgkin’s and non-Hodgkin’s lymphoma. Bone Marrow Transplant. 1995;15:299–303
  24. Gribben JG. Bone marrow transplantation for low-grade B-cell malignancies. Curr Opin Oncol. 1997;9:117–121
  25. Martinez C, Martino R, Brunet S. Allogeneic stem cell transplantation for advanced low-grade lymphoproliferative disorders: report of six cases. Haematologica. 1996;81:330–334
  26. van Besien KW, Mehra RC, Giralt SA. Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology. Am J Med. 1996;100:299–307
  27. Verdonck LF, Dekker AW, Lokhorst HM, Petersen EJ, Nieuwenhuis HK. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin’s lymphoma. Blood. 1997;90:4201–4205
  28. van Besien K, Sobocinski KA, Rowlings PA. Allogeneic bone marrow transplantation for low grade lymphoma. Blood. 1998;92:1832–1836
  29. Leuk Lymph. 1999;34:129–136
  30. Freedman AS, Gribben JG, Neuberg D. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood. 1996;88:2780–2786
  31. Zinzani PL, Bendandi M, Visani G. Adult lymphoblastic lymphoma: clinical features and prognostic factors in 53 patients. Leuk Lymphoma. 1996;23:577–582
  32. Weisdorf DJ. Bone marrow transplantation for acute lymphocytic leukemia (ALL). Leukemia. 1997;11:S20–S22
  33. Chopra R, Goldstone AH, Pearce R. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin’s lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry data. J Clin Oncol. 1992;10:1690–1695
  34. Stewart DA, Vose JM, Weisenburger DD. The role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Ann Oncol. 1995;6:263–266
  35. Dreger P, Von Neuhoff N, Kuse R. Sequential high-dose therapy and autologous stem cell transplantation for treatment of mantle cell lymphoma. Ann Oncol. 1997;8:401–403
  36. Andersen NS, Donovan JW, Borus JS. Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease. Blood. 1997;90:4212–4221
  37. Ketterer N, Salles G, Espinouse D. Intensive therapy with peripheral stem cell-transplantion in 16 patients with mantle cell lymphoma. Ann Oncol. 1997;8:701–704
  38. Kroger N, Hoffknecht M, Dreger P. Long-term disease-free survival of patients with advanced mantle-cell lymphoma following high-dose chemotherapy. Bone Marrow Transplant. 1998;21:55–57
  39. Freedman AS, Neuberg D, Gribben JG. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. J Clin Oncol. 1998;16:13–18
  40. Corradini P, Ladetto M, Astolfi M. Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle-cell lymphoma. Br J Haematol. 1996;94:376–378
  41. Adkins D, Brown R, Goodnough LT, Khoury H, Popovic W, DiPersio J. Treatment of resistant mantle cell lymphoma with allogeneic bone marrow transplantation. Bone Marrow Transplant. 1998;21:97–99
  42. Sohn SK, Bensinger W, Holmberg L. High dose therapy with allogeneic or autologous stem cell transplantation for relapsed mantle cell lymphoma: the Seattle experience. Proc Am Soc Clin Onc. 1998;17:17a
  43. Bergmann L. Present status of purine analogs in the therapy of chronic lymphocytic leukemias. Leukemia. 1997;11:S29–S34
  44. Dreger P, Schmitz N. The role of stem cell transplantation in the treatment of chronic lymphocytic leukemia. Leukemia. 1997;11:S42–S45
  45. Michallet M, Archimbaud E, Bandini G. HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry. Ann Internal Med. 1996;124:311–315
  46. Khouri IF, Keating M, Korbling M. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 1998;16:2817–2824
  47. DeMagalhaes-Silverman M, Donnenberg A, Hammert L. Induction of graft-versus-leukemia effect in a patient with chronic lymphocytic leukemia. Bone Marrow Transplant. 1997;20:1754–1757
  48. Rondon G, Giralt S, Huh Y. Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant. 1996;18:669–672
  49. Haberman TM, Pittelkow MR. Cutaneous T-cell lymphoma. In:  Abeloff MD,  Armitage JO,  Lichter AS,  Niederhuber JE editor. Clinical Oncology. New York: Churchill Livingstone,; 1995;p. 2149–2171
  50. Diamandidou E, Cohen P, Kurzrock R. Mycosis fungoides and Sezary syndrome. Blood. 1996;88:2385–2409
  51. Koeppel M, Stoppa A, Resbeut M. Mycosis fungoides and allogeneic bone marrow transplantation. Acta Derm Venereol. 1994;74:331–332
  52. Molina A, Nademanee A, Arber D, Forman S. Remission of refractory Sezary syndrome after bone marrow transplantation from a matched unrelated donor. Biol Blood Marrow Transplant. 1999;5:400–404
  53. Burt RK, Guitart J, Traynor A. Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides: evidence of a graft-versus-tumor effect. Bone Marrow Transplant. 2000;25:111–113
  54. Milpied N, Fielding AK, Pearce RM, Ernst P, Goldstone AH. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin’s disease. European Group for Blood and Bone Marrow Transplantation. J Clin Oncol. 1996;14:1291–1296
  55. Gajewski JL, Phillips GL, Sobocinski KA. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin’s disease. J Clin Oncol. 1996;14:572–578
  56. Jones RJ, Piantadosi S, Mann RB. High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin’s disease. J Clin Oncol. 1990;8:527–537
  57. Anderson J, Litzow M, Appelbaum F. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin’s disease: the 21-year Seattle experience. J Clin Oncol. 1993;11:2342–2350
  58. Dreger P, Kloss M, Petersen B. Autologous progenitor cell transplantation: prior exposure to stem cell- toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood. 1995;86:3970–3978
  59. Henry-Amar M, Joly F. Late complications after Hodgkin’s disease. Ann Oncol. 1996;7:115–126
  60. Miller JS, Arthur DC, Litz CE, Neglia JP, Miller WJ, Weisdorf DJ. Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy. Blood. 1994;83:3780–3786
  61. Darrington DL, Vose JM, Anderson JR. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol. 1994;12:2527–2534
  62. Traweek ST, Slovak ML, Nademanee AP, Brynes RK, Niland JC, Forman SJ. Myelodysplasia and acute myeloid leukemia occurring after autologous bone marrow transplantation for lymphoma. Leuk Lymphoma. 1996;20:365–372
  63. Witherspoon RP, Fisher LD, Schoch G. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med. 1989;321:784–789
  64. Curtis RE, Rowlings PA, Deeg HJ. Solid cancers after bone marrow transplantation. N Engl J Med. 1997;336:897–904
  65. Rill DR, Santana VM, Roberts WM. That autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood. 1994;84:380–383
  66. Brenner MK, Rill DR, Moen RC. Gene-marking to trace the origin of relapse after bone marrow transplantation. Lancet. 1993;341:85–86
  67. Appelbaum FR, Sullivan KM, Buckner CD. Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and stem cell transplantation. J Clin Oncol. 1987;5:1340–1347
  68. Santos GW, Saral R, Burns WH. Allogeneic, syngeneic and autologous marrow transplantation in the acute leukemias and lymphomas—Baltimore experiences. Acta Haematol. 1987;78:175–180
  69. Jones RJ, Ambinder RF, Piantadosi S, Santos GW. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone stem cell transplantation. Blood. 1991;77:649–653
  70. Ratanatharathorn V, Uberti J, Karanes C. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin’s lymphoma. Blood. 1994;84:1050–1055
  71. Soiffer RJ, Freedman AS, Neuberg D. CD6+T cell-depleted allogeneic bone marrow transplantation for non-Hodgkin’s lymphoma. Bone Marrow Transplant. 1998;21:1177–1181
  72. Juckett M, Rowlings P, Hessner M. T cell-depleted allogeneic bone marrow transplantation for high-risk non-Hodgkin’s lymphoma: clinical and molecular follow-up. Bone Marrow Transplant. 1998;21:893–899
  73. Mandigers CMPW, Raemaekers JMM, Schattenberg AVMB. Allogeneic bone marrow transplantation with T-cell-depleted marrow grafts for patients with poor-risk relapsed low-grade non-Hodgkin’s lymphoma. Br J Hematol. 1998;100:198–206
  74. Kolb HJ, Holler E. Adoptive immunotherapy with donor lymphocyte transfusions. Curr Opin Oncol. 1997;9:139–145
  75. Collins RH, Shpilberg O, Drobyski WR. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15:433–444
  76. van Besien KW, de Lima M, Giralt SA. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplant. 1997;19:977–982
  77. Salutari P, Sica S, Micciulli G, Rutella S, DiMario A, Leone G. Extramedullary relapse after allogeneic bone marrow transplantation plus buffy-coat in two high-risk patients. Haematologica. 1996;81:182–185
  78. Varadi G, Reuven O, Kapelushnik J. Graft-versus-lymphoma effect after allogeneic peripheral blood stem cell transplantation for primary central nervous system lymphoma. Leuk Lymph. 1999;34:185–190
  79. Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan LM, Ferrara JL. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood. 1997;90:3204–3213
  80. Slavin S, Nagler A, Naparstek E. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756–763
  81. Giralt S, Estey E, Albitar M. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997;89:4531–4536
  82. Grigg A, Bardy P, Byron K, Seymour JF, Szer J. Fludarabine-based non-myeloablative chemotherapy followed by infusion of HLA-identical stem cells for relapsed leukaemia and lymphoma. Bone Marrow Transplant. 1999;23:107–110
  83. Mehta J, Powles S, Singhal S, Iveson T, Treleaven T, Catovsky D. Clinical and hematologic response of chronic lymphocytic and prolymphocytic leukemia after allogeneic bone marrow transplantation with the onset of acute graft-versus-host disease: possible role of graft-versus-leukemia. Bone Marrow Transplant. 1996;17:371–375
  84. Nakao S, Miura Y, Zeng W. Induction of autocytotoxic T cells with cyclosporine and interferon-gamma for patients with non-Hodgkin’s lymphoma after transplantation of peripheral blood stem cells. J Allergy Clin Immunol. 1997;100:S65–S69
  85. Nagler A, Ackerstein A, Or R, Naparstek E, Slavin S. Immunotherapy with recombinant human interleukin-2 and recombinant interferon-alpha in lymphoma patients postautologous marrow or stem cell transplantation. Blood. 1997;89:3951–3959
  86. Massumoto C, Benyunes MC, Sale G. Close simulation of acute graft-versus-host disease by interleukin-2 administered after autologous bone marrow transplantation for hematologic malignancy. Bone Marrow Transplant. 1996;17:351–356
  87. Sykes M, Preffer F, McAfee S. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet. 1999;353:1755–1759
  88. Bonini C, Ferrari G, Verzeletti S. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science. 1997;276:1719–1724
  89. Socie G, Stone JV, Wingard JR. Long-term survival and late deaths after allogeneic bone marrow transplantation. N Engl J Med. 1999;341:14–21
  90. Rapoport AP, DiPersio JF, Martin BA. Patients > or = age 40 years undergoing autologous or allogeneic BMT have regimen-related mortality rates and event-free survivals comparable to patients < age 40 years. Bone Marrow Transplant. 1995;15:523–530
  91. Ferrara JL, Cooke KR, Pan L, Krenger W. The immunopathophysiology of acute graft-versus-host-disease. Stem Cells. 1996;14:473–489
  92. O’Reilly SE, Connors JM, Macpherson N, Klasa R, Hoskins P. Malignant lymphomas in the elderly. Clin Geriatr Med. 1997;13:251–263
  93. Reece D. Should high-risk patients with Hodgkin’s disease be singled out for heavier therapeutic regimens while low risk patients are spared such therapies?. Leuk Lymphoma. 1995;15:19–21
  94. Armitage JO. Autologous bone marrow transplantation for patients with aggressive non-Hodgkin’s lymphoma. Bone Marrow Transplant. 1992;10:62–63
  95. N Engl J Med. 1993;329:987–994
  96. Shad A, Magrath I. Non-Hodgkin’s lymphoma. Pediatr Clin North Am. 1997;44:863–890
  97. Fisher RI, Gaynor ER, Dahlberg S. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med. 1993;328:1002–1006
  98. Canellos GP, Anderson JR, Propert KJ. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327:1478–1484
  99. Nademanee AP, Forman SJ, Schmidt GM. Allogeneic bone marrow transplantation- for high-risk non-Hodgkin’s lymphoma during first complete remission. Blut. 1987;55:11–18
  100. Milpied N, Ifrah N, Kuentz M. Bone marrow transplantation for adult poor prognosis lymphoblastic lymphoma in first complete remission. Br J Haematol. 1989;73:82–87
  101. Troussard X, Leblond V, Kuentz M. Allogeneic bone marrow transplantation in adults with Burkitt’s lymphoma or acute lymphoblastic leukemia in first complete remission. J Clin Oncol. 1990;8:809–812
  102. De Witte T, Awwad B, Boezeman J. Role of allogenic bone marrow transplantation in adolescent or adult patients with acute lymphoblastic leukaemia or lymphoblastic lymphoma in first remission. Bone Marrow Transplant. 1994;14:767–774
  103. Robison LL. General principles of the epidemiology of childhood cancer. In:  Pizzo PA,  Poplack DG editor. Principles and Practices of Pediatric Oncology 3rd edn.. Philadelphia: J.B Lippincott–Raven; 1997;p. 1–10
  104. Shad A, Magrath IT. Malignant non-Hodgkin’s lymphomas in children. In:  Pizzo PA,  Poplack DG editor. Principles and Practices of Pediatric Oncology 3rd edn.. Philadelphia: Lippincott-Raven,; 1997;p. 545–587
  105. Kurtzberg J, Graham ML. Non-Hodgkin’s Lymphoma: biologic classification and implication for therapy. Pediatric Clin North Am. 1991;38:443–456
  106. Sandlund JT, Downing JR, Crist WM. Non-Hodgkin’s lymphoma in childhood. N Engl J Med. 1996;334:1238–1248
  107. Hunger SP, Link MP, Donaldson SS. ABVD/MOPP and low-dose involved-field radiotherapy in pediatric Hodgkin’s disease: the Stanford experience. J Clin Oncol. 1994;12:2160–2166
  108. Baker KS, Gordon BG, Gross TG. Autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin’s disease in children and adolescents. J Clin Oncol. 1999;17:825–831
  109. O’Leary M, Ramsey NKC, Nesbit ME. Bone marrow transplantation for non-Hodgkin’s lymphoma in children and young adults. Am J Med. 1983;74:497–501
  110. Chakravarti V, Kamani N, Bayever E. Bone marrow transplantation for childhood Ki-1 lymphoma. J Clin Oncol. 1990;8:657–660
  111. Lin KH, Su IJ, Chen RL. Peripheral T-cell lymphoma in childhood: a report of five cases in Taiwan. Med Pediatr Oncol. 1994;23:26–35
  112. Bureo E, Ortega JJ, Munoz A. Bone marrow transplantation in 46 pediatric patients with non-Hodgkin’s lymphoma. Bone Marrow Transplant. 1995;15:353–359
  113. Weisdorf D, Haake R, Blazar B. Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation. Transplantation. 1991;51:1197–1203
  114. Mundt AJ, Sibley G, Williams S, Hallahan D, Nautiyal J, Weichselbaum RR. Patterns of failure following high-dose chemotherapy and autologous bone marrow transplantation with involved field radiotherapy for relapsed/refractory Hodgkin’s disease. Int J Radiat Oncol Biol Phys. 1995;33:261–270
  115. Abrams RA, Liu PJ, Ambinder RF. Hodgkin and non-Hodgkin lymphoma: local radiation therapy after bone marrow transplantation. Radiology. 1997;203:865–870
  116. Pecego R, Hill R, Appelbaum FR. Interstitial pneumonitis following autologous bone marrow transplantation. Transplantation. 1986;42:515–517
  117. van der Jagt RH, Appelbaum FR, Petersen FB. Busulfan and cyclophosphamide as a preparative regimen for bone marrow transplantation in patients with prior chest radiotherapy. Bone Marrow Transplant. 1991;8:211–215
  118. Demirer T, Weaver CH, Buckner CD. High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy. J Clin Oncol. 1995;13:596–602
  119. Williams CD, Pearce R, Taghipour G, Green ES, Philip T, Goldstone AH. Autologous bone marrow transplantation for patients with non-Hodgkin’s lymphoma and CNS involvement: those transplanted with active CNS disease have a poor outcome—a report by the European Bone Marrow Transplant Lymphoma Registry. J Clin Oncol. 1994;12:2415–2422
  120. van Besien KW, Przepiorka D, Mehra R. Impact of preexisting CNS involvement on the outcome of bone marrow transplantation in adult hematologic malignancies. J Clin Oncol. 1996;14:3036–3042
  121. Emanuel DJ, Lucas KG, Mallory GB. Treatment of posttransplant lymphoproliferative disease in the central nervous system of a lung transplant recipient using allogeneic leukocytes. Transplantation. 1997;63:1691–1694
  122. Vandenberghe E, Pearce R, Taghipour G, Fouillard L, Goldstone AH. Role of a second transplant in the management of poor-prognosis lymphomas: a report from the European Blood and Bone Marrow Registry. J Clin Oncol. 1997;15:1595–1600
  123. de Lima M, van Besien KW, Giralt SA, Khouri IF, Mehra R, Andersson BS, et al. Bone marrow transplantation after failure of autologous transplant for non-Hodgkin’s lymphoma. Bone Marrow Transplant. 1997;19:121–127
  124. Slavin S, Naparstek E, Nagler A. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood. 1996;87:2195–2204
  125. Swinnen LJ. Treatment of organ transplant-related lymphoma. Hematol Oncol Clin North Am. 1997;11:963–973
  126. Heslop HE, Rooney CM. Adoptive cellular immunotherapy for EBV lymphoproliferative disease. Immunol Rev. 1997;157:217–222
  127. Cook RC, Connors JM, Gascoyne RD, Fradet G, Levy RD. Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation. Lancet. 1999;354:1698–1699
  128. McGuirk JP, Seropian S, Howe G, Smith B, Stoddart L, Cooper DL. Use of rituximab and irradiated donor-derived lymphocytes to control Epstein-Barr virus-associated lymphoproliferation in patients undergoing related haplo-identical stem cell transplantation. Bone Marrow Transplant. 1999;24:1253–1258
  129. Faye A, Van Den Abeele T, Peuchmaur M, Mathieu-Boue A, Vilmer E. Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders. Lancet. 1998;352:1285
  130. Waters TM, Bennett CL, Pajeau TS. Economic analyses of bone marrow and blood stem cell transplantation for leukemias and lymphoma: what do we know?. Bone Marrow Transplant. 1998;21:641–650
  131. Sweetenham JW. Economics of stem cell transplantation for lymphoma: counting the cost of living. Br J Cancer. 2000;82:81–84
  132. Lee S, Klar N, Weeks J. Predicting costs of stem-cell transplantation. J Clin Oncol. 2000;18:64–71
  133. Uyl-de Groot CA, Ossenkoppele GJ, Buijt I. Stem cell transplantations in patients with malignant lymphoma: costs in a Dutch university hospital in the period 1984–1995. J Hematother Stem Cell Res. 1999;8:619–625

PII: S0305-7372(00)90179-8

doi: 10.1053/ctrv.2000.0179

Cancer Treatment Reviews
Volume 26, Issue 6 , Pages 411-427 , December 2000

Article Tools